



Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic 
outcome of islet transplantation by suppressing IL-1β and islet cellular death  
 
Taisuke Matsuoka1, Gumpei Yoshimatsu1*, Naoaki Sakata1, Ryo Kawakami1, 5 
Tomoko Tanaka1, Teppei Yamada2, Yoichiro Yoshida2, Suguru Hasegawa2, 
Shohta Kodama1  
 
1. Department of Regenerative Medicine and Transplantation, Fukuoka 
University, Fukuoka, Japan 10 
2. Department of Gastroenterological surgery, Fukuoka University, Fukuoka, 
Japan 
 
*Corresponding author: Gumpei Yoshimatsu, Address; 7-45-1 Nanakuma 
Jonan-ku, Fukuoka, 814-0180, Japan, E-mail; gyoshimatsu@fukuoka-u.ac.jp, 15 
Tel: +81-92-801-1011 (ext. 3631) 
 
Keyword; Islet transplantation, Diabetes, NLRP3 inflammasome, 










Introduction; Early rejection is a critical issue to be overcome to achieve 
successful islet transplantation. NLRP3 inflammasome is a protein complex that 
mediates the maturation of pro-interleukin (IL)-1β and pro-IL-18 to IL-1β and 
IL-18, respectively, which induce cellular death. Here, we investigated the impact 5 
of NLRP3 inflammasome and the effect of its inhibition by MCC950 in a rodent 
model of islet transplantation. 
Method; We assessed the therapeutic effects of MCC950, a specific inhibitor of 
NLRP3 inflammasome, on gene expression, islet survival ratio and viability, and 
islet transplantation in mice. 10 
Results; NLRP3 inflammasome-related gene (Nlrp3 and Il1b) expression was 
upregulated in islets stimulated with proinflammatory cytokines and suppressed 
when incubated with MCC950. Survival ratio and viability of incubated islets 
were reduced by cytokine stimulation and improved by MCC950. Regarding islet 
transplantation, the number of apoptotic cells in transplanted islets was reduced 15 
by MCC950. Furthermore, the expression of IL-1β in transplanted islets, 
migration of macrophages around islets, and fluctuation of blood glucose levels 
were suppressed by MCC950. 
Conclusions; Our study revealed that NLRP3 inflammasome worsened the 
therapeutic outcomes of islet transplantation and that MCC950 administration 20 
improved glycaemic control in syngeneic mice that underwent islet 







Islet transplantation is a treatment option for insulin dependent diabetes mellitus 
that results from the autoimmune destruction of pancreatic beta cells. A phase 3 
clinical trial, the Clinical Islet Transplantation Consortium Protocol 07 trial 
(CIT-07), reported that 87.5% of recipients achieved eradication of severe 5 
hypoglycaemic events with excellent glycaemic control at 1 year after the first 
transplantation with a median haemoglobin A1c level of 5.6%. However, multiple 
islet infusion is required to achieve a satisfactory outcome. Long-term islet graft 
survival in CIT-07/08 is now being followed up. Clinical islet transplantation is 
performed by infusion into the liver via the portal vein; however, a large number 10 
of islets are lost in the early phase of islet transplantation 1. The major cause of 
the early rejection of islets is nonspecific innate immune responses represented by 
an instant blood-mediated inflammatory reaction (IBMIR). The activated innate 
immune system leads to a cytokine storm, involving tumor necrosis factor 
(TNF-α), interleukin-1β (IL-1β), and interferon-γ (IFN-γ) 2-5 . These cytokines 15 
activate macrophages immediately after the infusion of islets, and activated 
macrophages produce IL-1β, which accelerates the cytokine storm at the site of 
transplantation, causing a “negative chain” of events 6,7.  This series of 
inflammatory reactions causes severe damage to transplanted islets. Therefore, it 
is necessary to identify a strategy to regulate the nonspecific inflammatory 20 
response to promote the engraftment of islets and improve the therapeutic effect 
of islet transplantation. 
NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome is a 
protein complex in the cytoplasm that activates proinflammatory cytokines 
including IL-1β and IL-18 from pro-IL-1β and pro-IL-18, respectively. NLRP3 25 
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inflammasome comprises NLRP3 protein, an apoptosis-associated speck 
(ASC)-like protein and pro-caspase 1, which binds to the pyrin domain of NLRP3 
8. Once NLRP3 inflammasome is activated by signalling through Toll-like 
receptors, caspase-1 is activated and cleaves pro-IL-1β to IL-1β 9-11. Recent 
studies reported that NLRP3 inflammasome contributed to β cell dysfunction and 5 
death in type 1 and 2 diabetes 7,12-14. Furthermore, it affected the therapeutic 
effect of allogeneic organ transplantation 10 and worsened bacterial/viral 
infections 11. Although the regulation of NLRP3 inflammasome is a critical factor 
for the improvement of islet transplantation, the impact of NLRP3 inflammasome 
on islet transplantation is unclear. 10 
MCC950, a specific inhibitor of NLRP3 inflammasome was previously shown to 
regulate various inflammatory diseases that correlated with IL-1β 15,16 . In this 
study, we investigated the impact and regulation of NLRP3 inflammasome on islet 




NLRP3 inflammasome-related genes in cultured islets are upregulated by 
proinflammatory cytokines and suppressed by MCC950 
 First, we assessed the expression of NLRP3 inflammasome-related genes in 20 
MIN6 or islets stimulated by cytokines. We investigated the expression of Il1b 
and Nlrp3 genes in MIN6 incubated with a cytokine cocktail (CC) comprising 
TNF-α,  IFN-γ, and IL-1β, which are induced in the early phase of islet 
transplantation. Il1b and Nlrp3 were upregulated at 2 and 6 hours after incubation 
time-dependently (Figure 1a). Next, expression of NLRP3 inflammasome-related 25 
5 
 
genes was evaluated in islets incubated with lipopolysaccharide (LPS), a major 
cytokine stimulating NLRP3 inflammasome factor that signals through TLR4. 
Similar to MIN6, gene expression was upregulated by LPS stimulation (Figure 1b). 
The upregulation of Il1b and Nlrp3 was also seen in islets stimulated with CC, 
similar to LPS stimulation. The expression of Il1b and Nlrp3  genes was higher 5 
after cytokine stimulation compared with no cytokine stimulation (29.1 ± 14.1 
fold, Il1b, p < 0.001, and 107 ± 77.1 fold, Nlrp3, p  < 0.001, Figure 1c). 
Furthermore, the upregulated expressions of both genes were inhibited by 
MCC950 treatment (p < 0.001, Il1b and p < 0.05, Nlrp3, Figure 1c). These results 
suggested that inflammatory cytokine exposure induced the upregulation of 10 
NLRP3 inflammasome-related genes, which were suppressed by MCC950, 
although increase of caspase-1 activity in the islets with cytokine exposure was 
not seen by luciferase chemiluminescence assay (supplemental figure 1). 
 
Inhibition of NLRP3 inflammasome improves the islet survival rate and cell 15 
viability 
Next, the number of surviving islets cultured with the CC, CC and MCC950 (CC 
+ MCC950), or no treatment (control) were measured for 4 days to identify the 
impact of cytokine exposure on cultured islets and the effect of MCC950 on 
cultured islets. In the CC group, cultured islets had an irregular surface and some 20 
islets were destructively dispersed, whereas the morphology of islets was 
preserved (round-shape) in the control group. Of note, MCC950 protected the 
morphology of islets stimulated by cytokines (Figure 2a). The survival rate of 
cultured islets in the CC group was significantly decreased to 53.8% on day 4 
compared with 83.8% in the control group, and MCC950 significantly recovered 25 
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the survival rate of islets (69%, one-way ANOVA; p < 0.001, Control vs CC; p < 
0.0001, MCC950 vs CC; p = 0.0051. Figure 2b and c). Additionally, cell viability 
was calculated by Hoechst/PI staining to identify cellular death at 24 hours, which 
reflected the survival rate of islets. The number of PI stained dead cells was 
increased in cytokine stimulated islets, whereas MCC950 reduced the number of 5 
PI stained cells (Figure 2d). The cell viability of islets after 24 hours of culture 
was reduced by cytokine stimulation, but significantly improved by MCC950 
(Control vs CC vs CC + MCC950 treated group; 89.3% vs 66.4% vs 77.8%, 
one-way ANOVA; p < 0.001. Control vs CC; p < 0.001, Control vs MCC950; p = 
0.0081, CC vs MCC950; p = 0.009, Figure 2e). These results indicated NLRP3 10 
inflammasome induced the cellular death of islets after cytokine exposure, and 
that MCC950 improved islet survival by inhibiting NLRP3 inflammasome. 
 
Apoptosis is induced in islets after transplantation and attenuated by 
MCC950 administration 15 
The apoptosis of transplanted islets in the early phase of transplantation was 
assessed to elucidate the cellular death of islets in the liver. Terminal 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining revealed 
that numbers of apoptotic islet cells were increased time-dependently at 3, 6, and 
12 hours after transplantation in the control group. The apoptosis of transplanted 20 
islets peaked at 6 hours after transplantation. However, in the MCC950 treated 
group, apoptosis in islet cells was significantly reduced compared with the control 
group (Figure 3a). The calculated ratio of TUNEL positive cells in transplanted 
islets (TUNEL positive ratio) was significantly recovered by MCC950 
administration (control vs MCC950; 22.2 ± 8.6% vs 12.0 ± 4.2% at 6 hours; p = 25 
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0.0218, and 36.5 ± 12.9% vs 25.3 ± 7.9% at 12 hours; p= 0.0015. Figure 3b). This 
indicated that NLRP3 inflammasome was associated with the apoptosis of 
transplanted islets and that MCC950 suppressed apoptosis. 
 
Expression of IL-1β in the islet transplanted site is inhibited by MCC950 5 
administration 
To evaluate whether IL-1β produced by NLRP3 inflammasome was associated 
with islet transplantation, immunohistochemical staining for IL-1β in transplanted 
islet specimens recovered at 3, 6, and 12 hours after transplantation was 
performed. Histopathological findings revealed IL-1β expression in islets and 10 
around islets in the early phase of transplantation. In the control group, 
IL-1β-positive cells, which was pointed by black arrows, in and around 
transplanted islets were detected at 3 hours after transplantation and the numbers 
increased time-dependently (Figure 4a and b). However, MCC950 treatment 
significantly reduced the number of IL-1β-positive cells in and around 15 
transplanted islets at 3 hours after transplantation compared with the control 
group (Control group vs MCC950 group; 378.8 ± 116.0 cells/mm2 vs 66.0 ± 35.0 
cells/mm2 at 3 hours; p = 0.0043, 293.0 ± 77.0 cells/mm2 vs 121.9 ± 105.9 
cells/mm2 at 6 hours; p = 0.1226, and 559.1 ± 216.5 cells/mm2 vs 191.2 ±72.1 
cells/mm2 at 12 hours; p = 0.1122, Figure 4b). These results suggested that 20 
NLRP3 inflammasome induced IL-1β in transplanted islets, which was prevented 
by MCC950. 
 
Macrophage migration around transplanted islets is attenuated by MCC950 
To evaluate the number of macrophages around transplanted islets, liver samples 25 
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were stained for F4/80 at 3, 6, and 12 hours after transplantation. In the control 
group, numbers of F4/80+ macrophages observed mostly in the sinusoids of the 
liver around transplanted islets gradually increased time-dependently (Figure 5a). 
In the MCC950 treated group, F4/80+ macrophages were detected in the sinusoids 
of the liver around islets at 3 hours after transplantation similar to the control 5 
group. However, numbers of F4/80+  macrophages were reduced in the MCC950 
group at 6 and 12 hours after transplantation compared with the control group 
(Control vs MCC950 group; 50.6 ± 7.5 cells vs 50.7 ± 3.7 cells at 3 hours; p  = 
0.5067, 63.5 ± 6.5 cells vs 36.6 ± 2.4 cells at 6 hours; p = 0.0037, and 60.9 ± 6.7 
cells vs 32.1 ± 2.6 cells at 12 hours; p = 0.0015. Figure 5b). Therefore, MCC950 10 
attenuated the migration of macrophages around the transplanted islets by 
inhibiting NLRP3 inflammasome in the early phase after transplantation. 
 
MCC950 improves glycaemic control in diabetic mice after syngeneic islet 
transplantation 15 
Finally, the therapeutic effect of islet transplantation was compared between 
MCC950 treated and control groups. The blood glucose level was measured for 28 
days after islet transplantation. Blood glucose levels were significantly lower in 
the MCC950 group compared with the control group (repeated measures ANOVA; 
p = 0.0401, Figure 6a). On the other hand, body weight changing after islet 20 
transplantation was demonstrated as almost similar trend in both control and MCC 
treated group (Figure 6b). MCC950 might have another effect indirectly to affect 
appetite. Regarding plasma C-peptide level, MCC950 treated group had increased 
ΔC-peptide level in response to glucose stimulation  (Figure 6c). After 1 month, 
livers were removed to assess the histology of the islet engraftment. Engraftment 25 
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This study investigated the impact of NLRP3 inflammasome on islet 5 
transplantation. NLRP3 inflammasome is an intracellular sensor and its assembly 
leads to the caspase-1 dependent release of the proinflammatory cytokines, IL-1β 
and IL-18 17.  Additionally, NLRP3 inflammasome induces pyroptosis, an 
apoptosis pathway that leads to cellular death. We found that cytokine stimulation 
promoted NLRP3 inflammasome-related gene expression and impaired islet cell 10 
viability. We used the cytokine stimulation model to reflect inflammatory 
conditions during intrahepatic islet transplantation, which can impair islet 
engraftment. We also showed the therapeutic effects of MCC950, a small 
molecule that inhibits NLRP3 inflammasome, which was developed based on 
diarylsulfonylurea-containing compounds that are novel IL-1β  processing 15 
inhibitors 18,19. MCC950 administration suppressed NLRP3 inflammasome-related 
gene expression, improved islet viability, prevented the apoptosis of transplanted 
islets, reduced the production of IL-1β in transplanted islets and migration of 
macrophages, and improved the glycaemic control of islets after transplantation. 
Therefore, MCC950 might be a new therapeutic agent to improve islet 20 
transplantation. 
The inflammatory process of NLRP3 inflammasome was characterized as a 
two-step process including priming and activation 17. Priming of NLRP3 
inflammasome is initiated to upregulate the expression of inflammasome 
components. This upregulation is induced by the recognition of 25 
10 
 
pathogen-associated molecular patterns  (PAMPs), damage-associated molecular 
patterns (DAMPs), ATP, and cytokines. The second process involves activation 
and inflammasome formation 17,20. NLRP3 inflammasome is activated by the 
recognition of NLRP3 activators, such as DAMPs, reactive oxygen species (ROS), 
oxidant stress, and mitochondrial dysfunction. The activated inflammasome 5 
cleaves caspase-1 and activates pro-IL-1β to IL-1β. The current study found that 
TNF-α,  IFN-γ, and IL-1β  upregulated NLRP3 inflammasome-related gene 
expression in mouse islets. Furthermore, inhibition of NLRP3 inflammasome by 
MCC950 prevented the upregulation of these genes induced by proinflammatory 
cytokines. In the transplant model, histological analysis indicated IL-1β was 10 
produced in transplanted islets from early after transplantation, and was reduced 
by MCC950 especially at 3 hours after transplantation. Moreover, high numbers 
of F4/80+ macrophages that migrated around transplanted islets and within hepatic 
parenchyma near the islets were reduced by MCC950. These therapeutic effects 
on macrophages were seen after 6 hours, which was delayed compared with the 15 
suppressive effect on IL-1β production in islets. These results suggested that 
chemically and/or mechanically damaged islets released DAMPs and 
proinflammatory cytokines including IL-β, which triggered subsequent 
inflammatory reactions. Although the amount of IL-1β produced by islets was low 
compared with immune cells, it promoted inflammation during islet 20 
transplantation. The suppression of IL-1β production in islets reduced the 
migration of macrophages to the liver. Previous reports revealed that IL-1β was 
produced in human islets through NLRP3 inflammasome 7 and that NLRP3 
inflammasome was activated in rat islets by hypoxia 21. And IL-1β has known to 
lead to Fas receptor upregulation, NF-κB activation, β cell apoptosis, and 25 
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dysfunction 22. Our results suggested that NLRP3 inflammasome regulated IL-1β  
production in mouse islets and macrophages, and that MCC950 suppressed IL-1β  
production in transplanted islets and existing macrophages, and reduced the 
migration of macrophages around transplanted islets. These suppressive effects of 
IL-1β might contribute to attenuated glucose fluctuations after islet 5 
transplantation. 
NLRP3 inflammasome induces pyroptosis, a form of apoptosis. Recent studies 
reported the N-domain of gasdermin D (GSDMD) mediated proinflammatory 
pyroptosis 23-25. GSDMD has two domains (N-domain and C-domain). Activated 
caspase-1 and caspase-11 cleave GSDMD into two fragments. The N-domain of 10 
GSDMD forms pores on lipid membranes and induces pyroptosis through cell 
membrane disruption. Our study revealed that induction of NLRP3 inflammasome 
by cytokine stimulation or islet transplantation caused islet cellular apoptosis 
(pyroptosis), and that inhibition by MCC950 improved the cellular survival of 
islets in vitro and in vivo. Islets were damaged by chemical and mechanical 15 
manipulation during the isolation process, which induced apoptosis. Regarding 
NLRP3 associated apoptosis, Wang et al. reported that islet β cell apoptosis was 
mediated by NLRP3 inflammasome through the elevation of serum angiotensin II 
26, whereas the Lebreton group reported NLRP3 inflammasome activation was not 
involved in islet cell death induced by hypoxia 7. In our mouse islet transplant 20 
model, MCC950 restored islet damage induced during the isolation process. 
 IL-1β is an important inflammatory mediator responsible for islet dysfunction 
5,27,28. Therefore, the regulation of IL-1β is important to prevent early rejection 
and improve the therapeutic outcome of islet transplantation. Nazirrudin et al. 
reported an improved outcome for clinical islet transplantation by the combined 25 
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blockade of IL-1β and TNF-α using anakinra and etanercept 29. Additionally, 
IL-1β upregulated CXCL10 in islets, and the inhibition of CXCL10 improved the 
outcome of islet transplantation. MCC950 blocks NLRP3 inflammasome, which 
suppresses upstream IL-1β production. The effects of MCC950 were recently 
reported for metabolic diseases such as NASH. Auvro et al. showed that NLRP3 5 
inflammasome blockade by MCC950 reduced the number of macrophages in the 
livers of NASH mice 30 . Likewise, our study revealed that NLRP3 inflammasome 
blockade by MCC950 reduced the number of macrophages in livers during islet 
transplantation and that MCC950 improved the engraftment of islets by reducing 
apoptosis (pyroptosis). On the other hand, the role of IL-1β to β cell has 10 
paradoxical features regarding glucose metabolism associated with inflammatory 
cells as homeostasis, and IL-1β blockade could potentially affect β-cell 
physiological activity which was independent of engraftment after transplantation. 
While IL-1β promotes postprandial insulin secretion 31 and short-term exposure to 
macrophage-derived IL-1β stimulate insulin secretion, Donath et.al. described 15 
that long-term may exposure to IL-1β may lead to β-cell exhaustion 32. As the 
limitation of this study, we did not identify caspase-1 activity in islets under 
cytokine stimulation in in vitro assay shown in Supplemental Figure 1, despite 
upregulation of NLRP3 related inflammasome in the islets and increase of IL -1β 
positive cells after islet transplantation were seen. This discrepancy suggests that, 20 
in vivo condition, transplanted islets were affected by not only cytokine 
stimulation but also other factors which is still unknown. And to completely pass 
thorough the NLRP3 inflammasome pathway including caspase-1 activation, this 
unknown factor might be required. To clarify this unknown factor,  future studies 
should clarify the role of NLRP3 inflammasome in islet transplantation and the 25 
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detailed mechanism of pyroptosis inhibition by MCC950. 
In conclusion, we revealed that NLRP3 inflammasome worsened the  therapeutic 
outcomes of islet transplantat ion. Furthermore, MCC950 administration improved 
glycaemic control in a syngeneic mouse islet transplantation model by 




Materials and Methods 
Animals 10 
Nine-week-old male C57BL/6J mice, purchased from CLEA Japan Inc. (Tokyo, 
Japan), were used as diabetic recipients and donors for islet transplantation. All 
mice were bred under specific pathogen-free conditions. This study was approved 
by the Fukuoka University Animal Care and Use Committee (ID: 1808052) and 
carried out under the Fukuoka University Animal Experimentation Regulations. 15 
 
Islet isolation 
 Pancreata were expanded by an injection of collagenase solution (collagenase 
type V, Sigma-Aldrich, St. Louis, USA) into the pancreatic duct under laparotomy 
with general anaesthesia using isoflurane (Fujifilm Wako Pure Chemical Co., 20 
Osaka, Japan). Expanded pancreata were digested by incubating at 37°C for 18 
minutes with shaking. Digested tissue was washed with Hanks’ balanced salt 
solution (HBSS, Gibco-Thermo Fisher Scientific, Waltham, MA, USA), and islets 
were purified by discontinuous density gradient centrifugation using Biocoll 
(1.077 and 1.100 g/ml, Biochrom, Berlin, Germany). After collection of purified 25 
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islets, they were handpicked under a microscope for additional purification. 
Isolated islets were used in subsequent experiments after overnight culturing in 
Dulbecco’s modified Eagle’s medium (DMEM, Thermo Fisher Scientif ic, 
Waltham, MA, USA) supplemented of 10% foetal bovine serum (Thermo Fisher 
Scientific) and 1% Penicillin-Streptomycin (Thermo Fisher Scientific) at 37°C in 5 
5% CO2.  
 
Cell Culture 
The MIN6, β cell line, was cultured in Dulbecco’s modified Eagle medium 
(DMEM) containing 4,500 mg/dL glucose, supplemented with 10% foetal bovine 10 
serum and 1% antibiotics in 5% CO2 at 37°C33.  The cells were used for subsequent 
RT-PCR after reaching 70% confluence. 
 
Quantitative RT-PCR 
MIN6 cells or islets were incubated with a cytokine cocktail (DMEM containing 15 
5 ng/mL IL-1β  (Fujifilm Wako Pure Chemical Co.), 10 ng/mL TNF-α (Fujifilm 
Wako Pure Chemical Co.) and 50 ng/mL IFN-γ (Fujifilm Wako Pure Chemical 
Co.) for 4 hours to induce cytokine production within islets (defined as “CC”). 
The groups incubated with MCC950 (10 µM) or not treated were defined as “CC + 
MCC950” and “control”, respectively. After treatments, MIN6 cells or islets were 20 
lysed with TRIzol Reagent (Thermo Fisher Scientific) and RNA was extracted 
from lysates using the PureLink RNA Mini Kit (Thermo Fisher Scientific). RNA 
was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit 
(Thermo Fisher Scientific). Quantitative real-time PCR for cDNA was performed 
using the LightCycler96 System (Roche) with TB Green Premix Ex Ta  II (Takara 25 
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Bio Inc., Shiga, Japan) for amplification and detection. The expressions of Il1b 
and Nlrp3 were normalized to the expression of Rplp0. The primers were as 
follows: 5′-TCCAGGATGAGGACATGAGCAC-3′ (forward) and 
5′-GAACGTCACACACCAGCAGGTTA-3′ (reverse) for Il1b, 
5′-AATGCCCTTGGAGACACAGGA-3 ′ (forward) and 5 
5′-TGAGGTGAGGCTGCAGTTGTCTA-3 ′ (reverse) for Nlrp3, 
5′-GGCAGCATTTATAACCCTGAAGTG-3 ′ (forward) and 
5′-TGTACCCATTGATGATGGAGTGTG-3′ (reverse) for Rplp0. 
 
Islet survival assay 10 
Fifty islets were cultured in 2 mL of DMEM with the cytokine cocktail (CC), the 
cytokine cocktail and 10 µM MCC950 (CC + MCC950), or were untreated 
(control), at 37°C in 5% CO2 for 4 days. The survival ratio of cultured islets was 
defined as the number of islets/the number of islets at preincubation and was 
measured every day. 15 
 
Cell viability of islets assay 
Isolated islets were incubated with the cytokine cocktail containing-media for 24 
hours in the presence of 0 and 10 µM MCC950. Control islets were untreated with 
cytokine cocktail and MCC950. Then, islets were stained with propidium iodide 20 
(PI, Sigma-Aldrich) to detect dead cells and Hoechst 33342 (Sigma-Aldrich) to 
detect viable cells 34. We obtained images with a fluorescence microscope 
(BZ-X710, Keyence, Osaka, Japan). The viability of cultured islets was 
determined as follows: viability of cultured islets (%) = (number of viable 





Diabetes was induced by streptozotocin (STZ; 180 mg/kg mouse body weight, 
Sigma-Aldrich) injection into the tail vein of C57BL/6J mice. Diabetic mice with 
a blood glucose level of 400–600 mg/dL for two consecutive days at 3–5 days 5 
after the administration of streptozotocin were used as recipients. For 
transplantation, 170 islet equivalents (IEQs) were transplanted into the liver via 
the portal vein. The treatment group (defined as the MCC950 group), was 
intraperitoneally (ip) injected with 25 mg/kg MCC950 at 30 minutes before and 6, 
24, and 48 hours after transplantation. For the control group, phosphate buffered 10 
saline (PBS) was injected at the same time points as the MCC950 group. 
Non-fasting blood glucose levels and body weight were monitored in all 
recipients twice a week until 28 days after islet transplantation. After 20 days 
after transplant for each 8 mice per group, plasma C-peptide level was measured 
by enzyme-linked immunosorbent assay (ELISA). Blood samples as 15 
pre-stimulation were collected from tail vein after 12-14 hours fasting. And 20% 
glucose solution was intraperitoneally injected at dose of 2g / kg of mice body 
weight. Blood samples as post-stimulation were collected at 30 minutes after 
glucose injection. Plasma samples were obtained by centrifugation at 3,000 rpm 
for 5 minutes, and plasma C-peptide level was measured using LEBIS mouse 20 
C-peptide ELISA kit, U type (FUJIFILM Wako Shibayagi Corporation, Shibkawa, 
Japan). ΔC-peptide was calculated as plasma C-peptide level of post-stimulation 
subtracted by plasma C-peptide level of pre-stimulation (pg/mL). 
 
Histopathology and Immunohistochemistry 25 
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The liver was removed at 3, 6, or 12 hours, or 30 days after transplantation under 
general anaesthesia and fixed in 10% formaldehyde solution. The samples were 
embedded in paraffin, cut into 3-μm-thick sections, deparaffinized in xylene, and 
rehydrated in ethanol. The sections were stained with haematoxylin and eosin 
(HE), and immunohistochemical staining was performed to detect islets (insulin), 5 
IL-1β, macrophages (F4/80), or apoptotic cells using TUNEL. The primary 
antibodies for immunohistochemistry were rabbit monoclonal anti-insulin 
antibody (diluted 1:5000; ab181547, Abcam plc, Cambridge, UK), polyclonal goat 
IgG anti-mouse IL-1β/IL-1F2 antibody (diluted 1:25; R&D Systems Inc), and 
rabbit monoclonal anti-F4/80 antibody (diluted 1:250; #70076, Cell Signaling 10 
Technology, Danvers, MA, USA). After incubation of the primary antibody, 
donkey anti-rabbit secondary antibody (diluted 1:500; ab97082 or ab6802, Abcam 
plc) or donkey anti-goat IgG H&L (HRP polymer, for IL-1β staining; Abcam) was 
applied. To detect the target cells, a Warp Red Chromogen Kit (for insulin; 
Biocare Medical, Pacheco, CA, USA BRR806AH) and diaminobenzidine (DAB; 15 
for IL-1β and F4/80) were used. Regarding TUNEL staining, a TdT In Situ 
Apoptosis Detection Kit (R&D Systems, Inc, Minneapolis, MN USA 481030-k) 
was used following the manufacturer ’s instructions. Images were captured using a 
BZ-X710 microscope and imaging analysis was performed using ImageJ software 
(National Institute of Mental Health, Bethesda, Maryland, USA). 20 
 
Statistical analysis 
Data are shown as the means ± standard error of the mean (SEM).  Differences 
were assessed by Welch’s test for parametric data with unequal variances or 
Wilcoxon rank sum test for non-parametric data between two groups, one-way 25 
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ANOVA for data among three groups, or repeated measurement ANOVA for the in 
vitro survival rate and blood glucose trend after transplantation. When one-way 
ANOVA was applied, the Tukey–Kramer HSD test was used to identify significant 
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Figure legend 
Figure 1. Upregulation of NLRP3 inflammasome-related genes in cultured 
islets 
a. Gene expressions of Il1β and Nlrp3 in MIN6 incubated with a cytokine cocktail 25 
23 
 
for 0, 2, and 6 hours. b. Gene expressions of Il1β and Nlrp3 in isolated islets 
incubated with or without (control) lipopolysaccharide (LPS). c. Isolated islets 
were incubated with a cytokine cocktail or MCC950. Gene expressions of Il1β and 
Nlrp3 in isolated islets with cytokine stimulation (CC), CC and 10 µM of 
MCC950 (CC + MCC950), or no treatment (control). Data are shown as means ± 5 
standard error (SEM). Significant differences are indicated as *p <0.05, **p <0.01, 
***p <0.001. 
 
Figure 2. Inhibition of NLRP3 inflammasome improves the islet survival rate 
and cell viability under cytokine cocktail stimulation 10 
a. Morphological changes of islets cultured with the cytokine cocktail (CC), CC 
and MCC950 (CC + MC950), or no treatment (control) for 4 days. b. The change 
in survival rate of cultured islets in CC, CC + MCC950, and control groups for 4 
days (n=5 for each group). c. Survival rate of cultured islets at 4 days. d. 
Hoechst/propidium iodide (PI)-stained islets at 24 hours in CC, CC + MCC950, 15 
and control groups. Blue: viable, red: dead. e. Viability of cultured islets at 24 
hours in CC, CC + MCC950, and control groups (n=9 for each group). 
 
Figure 3. Expression of terminal deoxynucleotidyl transferase dUTP nick end 
labelling (TUNEL) positive cells in transplanted islets 20 
a. Diabetic recipient mice treated with or without MCC950 were transplanted with 
syngeneic islets (MCC950 or control group, respectively). Livers were recovered 
at 3, 6, and 12 hours after transplantation. Sections were stained for insulin (red: 
left) and TUNEL-positive apoptotic cells (brown: right). b. The ratio of TUNEL 
positive cells in the islet area at 3, 6, and 12 hours after transplantation in 25 
24 
 
MCC950 (black) and control (grey) groups. Data are shown as means ± SEM. 
Statistics were performed by the Student’s t-test. Significant differences are 
indicated as *p <0.05. 
 
Figure 4. Expression of IL-1β in transplanted sites 5 
a. Specimens of transplanted islets at 3, 6, and 12 hours after transplantation 
stained for insulin (green), IL-1β (red), and nuclei (blue). b. The number of IL-1β 
positive cells/islet area in MCC950 (black) and control (grey) groups. Data are 
shown as means ± SEM. Significant differences are indicated as *p <0.05. 
 10 
Figure 5. Expression of F4/80 positive cells 
a. Specimens of transplanted islets at 3, 6, and 12 hours after transplantation 
stained for insulin (red) and F4/80 (brown). b. The number of F4/80 positive cells 
around transplanted islets in MCC950 (black) and control (grey) groups. Data are 
shown as means ± SEM. Significant differences are indicated as *p <0.05, **p 15 
<0.01, ***p <0.001. 
 
Figure 6. Effect of an NLRP3 inflammasome inhibitor on islet transplantation 
a. Blood glucose profiles in MCC950 and control groups 28 days after 
transplantation. b. Body weight changing was demonstrated for 28 days after 20 
transplantation. c. ΔC-peptide level by glucose stimulation was demonstrated as a 
bar graph. d. Histological examination at 30 days after transplantation to detect 
engrafted islets. Data are shown as means ± SEM. Significant differences are 
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Materials and Method 
Assessment of caspase-1 activity on islets using luciferase assay system 
Isolated islets were incubated for 0, 3, 6, 12, 24 hours in RPMI based culture medium with cytokine 
cocktail (TNFα, IFNγ, IL-1β; CC group), without cytokine cocktail (Control group) or cytokine 
cocktail and MCC950 (CC + MCC950 group). After that, cellular caspase-1 activity on the islets was 
assessed using Caspase-Glo 1 inflammasome assay kit (Promega, Madison, WI, USA). Caspase-1 
activity through chemiluminescence by luciferase was measured according to the manufacture-
provided protocol. Chemiluminescence was measured by Spark (TECAN, Männedorf, Switzerland). 
 
Result 
Increase of caspase-1 activity in the islets with cytokine exposure was not seen by luciferase 
chemiluminescence assay (supplemental figure 1). As the limitation of this study, we could not identify 
caspase 1 activity in islets under cytokine stimulation in in vitro assay shown in Supplemental Figure 
1, despite upregulation of NLRP3 related inflammasome in the islets and increase of IL-1β positive 
cells after islet transplantation were seen. This discrepancy suggests that, in vivo condition, 
transplanted islets were affected by not only cytokine stimulation but also other factors which is still 
unknown. And to completely pass thorough the NLRP3 inflammasome pathway including caspase-1 
activation, this unknown factor might be required. To clarify this unknown factor, future studies should 
clarify the role of NLRP3 inflammasome in islet transplantation and the detailed mechanism of 
pyroptosis inhibition by MCC950. 
 
Figure legend 
Supplemental Figure 1. Caspase-1 activity of islets.  
Isolated islets were incubated for 0, 3, 6, 12, 24 hours in RPMI based media as Control group, in the 
media with cytokine cocktail as CC group, and in the media with cytokine cocktail and MCC950 as 
CC + MCC950 group (n=4 per each group). Data are shown as means ± SEM. 
Supplemental figure 1
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